Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/NS-2359> ?p ?o }
Showing triples 1 to 75 of
75
with 100 triples per page.
- NS-2359 abstract "NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant, but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company. NS-2359 was also in clinical trials for the treatment of ADHD, phase II having been completed in 2007. A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.Another scientific article on NS-2359 was recently (2011) published. As can be seen from reading the abstract to the citation, the compound failed to perform in clinical trials for the treatment of depression.".
- NS-2359 atcPrefix "none".
- NS-2359 iupacName "(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane".
- NS-2359 pubchem "11408320".
- NS-2359 thumbnail NStwothreefivenine.png?width=300.
- NS-2359 wikiPageID "22602885".
- NS-2359 wikiPageLength "3434".
- NS-2359 wikiPageOutDegree "14".
- NS-2359 wikiPageRevisionID "678209455".
- NS-2359 wikiPageWikiLink Antidepressant.
- NS-2359 wikiPageWikiLink Attention_deficit_hyperactivity_disorder.
- NS-2359 wikiPageWikiLink Category:Chloroarenes.
- NS-2359 wikiPageWikiLink Category:Ethers.
- NS-2359 wikiPageWikiLink Category:Serotonin-norepinephrine-dopamine_reuptake_inhibitors.
- NS-2359 wikiPageWikiLink Category:Tropanes.
- NS-2359 wikiPageWikiLink Clinical_trial.
- NS-2359 wikiPageWikiLink Cocaine.
- NS-2359 wikiPageWikiLink Drug_development.
- NS-2359 wikiPageWikiLink GlaxoSmithKline.
- NS-2359 wikiPageWikiLink Phases_of_clinical_research.
- NS-2359 wikiPageWikiLink Serotonin–norepinephrine–dopamine_reuptake_inhibitor.
- NS-2359 wikiPageWikiLink Tesofensine.
- NS-2359 wikiPageWikiLink Therapy.
- NS-2359 wikiPageWikiLinkText "GSK-372,475".
- NS-2359 wikiPageWikiLinkText "NS-2359".
- NS-2359 atcPrefix "none".
- NS-2359 c "15".
- NS-2359 cl "2".
- NS-2359 h "19".
- NS-2359 iupacName "-3".
- NS-2359 molecularWeight "300.223".
- NS-2359 n "1".
- NS-2359 o "1".
- NS-2359 pubchem "11408320".
- NS-2359 smiles "Clc1cccCCC3NC2CC3".
- NS-2359 verifiedrevid "424915685".
- NS-2359 wikiPageUsesTemplate Template:Adrenergics.
- NS-2359 wikiPageUsesTemplate Template:Drugbox.
- NS-2359 wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- NS-2359 wikiPageUsesTemplate Template:Phenyltropanes.
- NS-2359 wikiPageUsesTemplate Template:Reflist.
- NS-2359 subject Category:Chloroarenes.
- NS-2359 subject Category:Ethers.
- NS-2359 subject Category:Serotonin-norepinephrine-dopamine_reuptake_inhibitors.
- NS-2359 subject Category:Tropanes.
- NS-2359 hypernym Inhibitor.
- NS-2359 type ChemicalSubstance.
- NS-2359 type Drug.
- NS-2359 type Group.
- NS-2359 type Alkaloid.
- NS-2359 type Chemical.
- NS-2359 type Drug.
- NS-2359 type Ester.
- NS-2359 type Ether.
- NS-2359 type Group.
- NS-2359 type Heterocycle.
- NS-2359 type Inhibitor.
- NS-2359 type Organohalide.
- NS-2359 type Psychoanaleptic.
- NS-2359 type Redirect.
- NS-2359 type Stimulant.
- NS-2359 type Organohalide.
- NS-2359 type ChemicalObject.
- NS-2359 type Thing.
- NS-2359 type Q8386.
- NS-2359 comment "NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant, but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company. NS-2359 was also in clinical trials for the treatment of ADHD, phase II having been completed in 2007.".
- NS-2359 label "NS-2359".
- NS-2359 sameAs Q6955224.
- NS-2359 sameAs m.05z_m2n.
- NS-2359 sameAs NS-2359.
- NS-2359 sameAs NS-2359.
- NS-2359 sameAs Q6955224.
- NS-2359 wasDerivedFrom NS-2359?oldid=678209455.
- NS-2359 depiction NStwothreefivenine.png.
- NS-2359 isPrimaryTopicOf NS-2359.